However, using a five-year federal model, the Centers for Medicare & Medicaid Services will negotiate pricing and coverage terms on GLP-1s for Medicare Part D plans and participating state Medicaid agencies beginning in 2027
So just mostly because no ones looking at it, no ones investigating
Many people experience no symptoms until they reach a higher dose
Personal Opinion: Having reviewed hundreds of case reports and clinical studies, I believe testosterone optimization represents the single most underutilized tool in mens metabolic health
Weight loss through any means typically reduces hsCRP, but the magnitude of reduction with GLP-1 based therapies appears to exceed what weight loss alone would predict
These symptoms, while typically mild to moderate, can be severe enough to affect daily life